A combination model of PT, RDW, PDW, RAVD, and NXT effectively predicted high-quality Time in Therapeutic Range (≥70%) during warfarin therapy with an AUC of 0.900 (95% CI 0.848-0.952).
Cohort (n=136)
No
Can a combination of clinical indicators (PT, RDW, PDW, RAVD, and NXT) predict high-quality Time in Therapeutic Range (TTR ≥70%) in patients with atrial fibrillation receiving warfarin?
A novel prediction model combining PT, RDW, PDW, RAVD, and NXT can effectively predict whether atrial fibrillation patients on warfarin will achieve a high-quality Time in Therapeutic Range (≥70%).
Effect estimate: AUC 0.900 (95% CI 0.848-0.952)
Objective To explore the factors affecting the Time in Therapeutic Range (TTR) of warfarin anticoagulation therapy and propose a novel TTR prediction model. Methods Patients with atrial fibrillation who received warfarin anticoagulation therapy and had complete follow-up data between January 2020 and September 2021 at The First Hospital of Jiujiang City were retrospectively included. All participants were divided into a high quality TTR group and a non high quality TTR group based on whether TTR ≥70%. The predictive value of clinical indicators for TTR was assessed utilizing the area under the receiver operating characteristic curve (AUC). Results A total of 136 patients were included in the final analysis. The results showed that PT, RDW, PDW, RAVD, and NXT were significantly associated with TTR. The combination model of PT, RDW, PDW, RAVD, and NXT resulted in the highest AUC of 0.900 (95% CI: 0.848-0.952) with the specificity (0.835) and sensitivity (0.843). Conclusion PT, RDW, PDW, RAVD, and NXT were important influencing factors for TTR in warfarin anticoagulation therapy. Combining these clinical indicators can effectively predict the TTR of warfarin anticoagulation therapy.
LUO et al. (Thu,) conducted a cohort in Atrial Fibrillation (n=136). Combination model of PT, RDW, PDW, RAVD, and NXT was evaluated on Time in Therapeutic Range (TTR) ≥70% (AUC 0.900, 95% CI 0.848-0.952). A combination model of PT, RDW, PDW, RAVD, and NXT effectively predicted high-quality Time in Therapeutic Range (≥70%) during warfarin therapy with an AUC of 0.900 (95% CI 0.848-0.952).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: